Additional file 1 of Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
Additional file 1: Figure S1. Proportion of Patients Reporting PRO Scores ≥ Normative Values at Baseline and weeks 12 and 24. aABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (100 kg: 1,000 mg). ABA, abatacept; BL, baseline; EQ-5D-5L (index score), EQ-5D 5-Level; FACIT-F, Functional Assessment of...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Bild |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!